Filing identity and reporting period
The supplied filing is an IsoRay, Inc. Form 10-Q for the quarter ended September 30, 2018 (the company’s fiscal first quarter of 2019), not a filing identified as Perspective Therapeutics, Inc. or 2018 calendar Q1. Verify that this is the intended filing before relying on the figures below. Unless stated otherwise, financial amounts are in thousands of dollars.
IsoRay manufactures and sells Cesium-131 brachytherapy seeds for cancer treatment. Its unaudited consolidated statements cover the three months ended September 30, 2018, compared with the same period in 2017.
Financial performance and position
| Metric | Quarter ended September 30, 2018 | Prior-year quarter |
|---|---|---|
| Net product sales | $1,562 | $1,211 |
| Gross profit / margin | $524 / 34% | $265 / 22% |
| Operating expenses | $2,042 | $1,817 |
| Operating loss | ($1,518) | ($1,552) |
| Net loss | ($1,508) | ($1,546) |
| Basic and diluted loss per share | ($0.02) | ($0.03) |
| Net cash used in operating activities | ($1,612) | ($1,661) |
- Sales grew 29%. Prostate brachytherapy sales increased 27% to $1,376; other brachytherapy sales rose 46% to $186. Gross margin improved as revenue grew faster than product costs.
- Research and development expense was $420, including $394 of proprietary R&D and $26 of collaboration costs net of reimbursement. Sales and marketing expense was $649; general and administrative expense was $973.
- At September 30, cash and cash equivalents were $2,193, short-term investments were $7,000, and restricted cash was $181. Current assets were $11,268 and current liabilities $1,637; working capital was $9,631 and the current ratio 6.88.
- Total assets were $13,344 and total liabilities $2,235, including a $598 asset retirement obligation. The balance sheet presents no borrowings or other debt balance.
- Operating cash use was partly offset by $7,494 of financing cash proceeds. Investing cash use was $6,289, largely reflecting purchases of short-term investments; cash, cash equivalents, and restricted cash declined $407 to $2,374.
Material changes and financing
- On July 11, 2018, IsoRay sold 11 million common shares at $0.75 per share for $8.25 million gross proceeds; cash offering expenses were approximately $0.75 million. The company reported $7.494 million in net financing cash proceeds and said the proceeds had not yet been used.
- The offering included warrants for up to 5.5 million shares at $0.75, exercisable beginning January 11, 2019, plus placement-agent warrants for 330,000 shares at $0.9375. Cash exercise could provide up to $4.434 million gross, but is not assured.
- Common shares outstanding increased from 56.3 million at June 30 to 67.3 million at September 30. The company reported no material impact from adopting the new revenue recognition standard.
Outlook, commentary, and risks
- Management said sales growth reflected a full sales team, renewed marketing efforts, and new and reactivated accounts. It reported exceeding its 25% fiscal-2019 revenue-growth target in this quarter, but gave no assurance that growth would continue.
- Management estimated cash-flow break-even in three to five years only if its growth strategy succeeds and no extraordinary expenses arise. It said the recent offering was expected to fund operations for the next fiscal year without another capital raise; future financing could nevertheless dilute shareholders.
- The company planned approximately $215 of further spending over nine months on production automation. It had invested approximately $430 in automation through quarter-end. A new production and administration facility was designed, but construction depended on obtaining financing.
- Customer concentration is significant: five customers generated approximately 48% of quarterly revenue, and one physician group accounted for approximately 25%. Management warned that losing a major customer could materially harm revenue; prostate treatment also faces competition from alternatives.
- Cesium-131 supply depends in part on third-party arrangements. The filing describes uncertainty around future supply agreements and the quantity ultimately obtained from enriched barium. International revenue was $18; international sales were described as immaterial overall.
- Other brachytherapy revenue may fluctuate because adoption depends on a small group of innovative physicians. The filing reported no legal proceedings, no off-balance-sheet arrangements, and no material changes in risk factors other than customer concentration. Management concluded disclosure controls were effective.
Important facts to verify
- Confirm the filing identity and period: the source is IsoRay’s quarter ended September 30, 2018, not Perspective Therapeutics’ 2018 Q1.
- Assess whether the 29% sales increase and improved gross margin are repeatable, particularly given quarterly volatility in non-prostate sales.
- Review exposure to the five customers representing 48% of revenue and to competition in prostate treatment.
- Verify Cesium-131 supply continuity and the status and economics of the new facility and remaining automation investment.
- Track operating cash use, use of offering proceeds, and any warrant exercises or additional financing needs.